Form 4: Soleno Therapeutics Director Mario Ernest Acquires 62,000 Shares and Warrants

Director Mario Ernest purchased 62,000 shares and warrants of Soleno Therapeutics at $4.50 per share, while also adjusting previously reported holdings.

Summary

• On May 21, 2024, Mario Ernest, a director of Soleno Therapeutics Inc., acquired 62,000 shares of common stock at a price of $4.50 per share.
• The same day, Mario Ernest also acquired warrants to purchase 62,000 shares of common stock at an exercise price of $4.50, expiring on March 31, 2027.
• Following these transactions, Mr. Ernest directly owns 186,566 shares of Soleno Therapeutics.
• An internal review led to an adjustment of the reporting person's holdings.
• Additionally, 21,789 shares are held indirectly through the Mildred Mario Nonexempt Trust, where Mr. Ernest serves as a co-trustee.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director purchasing shares at $4.50 indicates some confidence, but the adjustment of holdings suggests a need for careful monitoring.

Positives

• A director's purchase of shares and warrants can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (directors, officers, and 10% owners) of a publicly traded company buy or sell the company's securities. These filings provide transparency into insider transactions and can be used by investors to gauge management's sentiment about the company's prospects.

Stakeholder Impact

• The director's purchase could positively influence shareholder sentiment.

Key Dates